87789-43-3

Upstream product

• 87-65-0 2,6-Dichlorophenol 
• 123-19-3 4-heptanone 
• 19481-82-4 2-bromopropionitrile 
• 87789-40-0 (+)-ethyl 2-(2,6-dichlorophenoxy)propionate 
• 1206899-43-5 (-)-2-(2,6-dichlorophenoxy)propionamide 
• 1617-17-0 2-chlorpropionitrile 

Downstream Products

• 73372-53-9 lofexidine 
• 101934-13-8 C₁₁H₁₃Cl₂NO₂*ClH 
• 101934-15-0 (S)-2-(2,6-Dichloro-phenoxy)-propionimidic acid ethyl ester; hydrochloride 
• 81447-79-2 (+)-Lofexidine 
• 101934-16-1 1,3-Dichloro-2-((S)-2,2,2-triethoxy-1-methyl-ethoxy)-benzene 
• 21498-08-8 lofexidine hydrochloride 

Relevant academic research and scientific papers

Rac- and R-(+)-[4,4′,5,5′-2H4]-2- (1′-[2″,6″-dichlorophenoxy]-ethyl)-Δ2- imidazoline (lofexidine)

The synthesis of the d4-forms of rac- and R-lofexidine was accomplished. Two methods are described; one method is a two-step synthesis of rac-d4-lofexidine from 2-chloropropionitrile, the second method is a three-step preparation of R-d4-lofexidine in absolute enantiomeric purity from S-methyl lactate. The commercial availability of R-methyl lactate makes this latter enantioselective synthesis applicable also to the synthesis of S-d4- lofexidine. These procedures also conserve the utilization of the relatively expensive [1,1′,2,2′-2H 4]ethylene diamine precursor. The availability of S- and R-d 4-lofexidines will enable pharmacokinetic studies to be carried out to determine if differential in vivo metabolism of the two enantiomers of lofexidine occurs. Copyright

Chemistry of Lofexidine

The systematic syntheses and pharmacological studies of numerous imidazolines aryloxyalkyl-substituted in the 2-position show that substitution of the aryl residue in the 2,6-position by halogen and addition of a side-chain to the alkyl residue results in compounds with marked antihypertensive activity. 2-[1-(2,6-Dichlorphenoxy)-ethyl]-2-imidazoline hydrochloride (lofexidine, Lofetesin and Loxacor) exhibits the most marked hypotensive activity. The synthesis and physico-chemical properties of lofexidine are described.

Imidazoline derivatives and processes for the production thereof

2-[α-(2,6-DICHLOROPHENOXY)-ETHYL]-Δ2 -IMIDAZOLINE, AND PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, WHICH PROVIDE VASOACTIVITY AND HYPOTENSIVE ACTIVITY.